

Azfar Zaman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9523114/publications.pdf>

Version: 2024-02-01

41
papers

1,483
citations

516710

16
h-index

330143

37
g-index

43
all docs

43
docs citations

43
times ranked

2330
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Role of Sex-Specific Flow Threshold in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , 2022, 36, 164-165.	0.8	1
2	Clinical outcomes of percutaneous coronary intervention for chronic total occlusion in prior coronary artery bypass grafting patients. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 74-84.	1.7	7
3	A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI. <i>International Journal of Cardiology</i> , 2022, 347, 1-7.	1.7	3
4	Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial. <i>EuroIntervention</i> , 2022, 18, 492-502.	3.2	8
5	Lipoprotein(a): Insights for the Practicing Clinician. <i>Journal of Clinical Medicine</i> , 2022, 11, 3673.	2.4	2
6	The Predictive Value of CHA2DS2-VASc Score on In-Hospital Death and Adverse Periprocedural Events Among Patients With the Acute Coronary Syndrome and Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention: A 10-Year National Inpatient Sample (NIS) Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 29, 61-68.	0.8	12
7	Pharmacology before, during and after percutaneous coronary intervention. <i>Heart</i> , 2021, 107, 585-592.	2.9	4
8	The ultra-thin strut sirolimus-eluting coronary stent: SUPRAFLEX. <i>Future Cardiology</i> , 2021, 17, 227-237.	1.2	5
9	Survival relative to pacemaker status after transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E444-E452.	1.7	5
10	Prospective Multicenter Randomized All-Comers Trial to Assess the Safety and Effectiveness of the Ultra-Thin Strut Sirolimus-Eluting Coronary Stent Supraflex. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010312.	3.9	10
11	Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium. <i>Catheterization and Cardiovascular Interventions</i> , 2021, .	1.7	1
12	In-hospital gastrointestinal bleeding following percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 109-117.	1.7	5
13	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	1.7	6
14	Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 249.	7.4	33
15	Transcatheter aortic valve implantation via surgical subclavian versus direct aortic access: A United Kingdom analysis. <i>International Journal of Cardiology</i> , 2020, 308, 67-72.	1.7	4
16	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020, 42, e49-e58.	1.2	23
17	Percutaneous Coronary Intervention and Outcomes in Patients With Lymphoma in the United States (Nationwide Inpatient Sample [NIS] Analysis). <i>American Journal of Cardiology</i> , 2019, 124, 1190-1197.	1.6	15
18	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1833-1840.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Temporal trends and inequalities in coronary angiography utilization in the management of non-ST-Elevation acute coronary syndromes in the U.S.. Scientific Reports, 2019, 9, 240.	3.3	25
20	Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome. Clinical Drug Investigation, 2019, 39, 495-502.	2.2	3
21	Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet, The, 2019, 393, 987-997.	13.7	72
22	Temporal trends and predictors of time to coronary angiography following non-ST-elevation acute coronary syndrome in the USA. Coronary Artery Disease, 2019, 30, 159-170.	0.7	10
23	Clinical outcomes in unselected patients treated with the PROMUS Element platinum-chromium, everolimus-eluting stent: Final five-year results from the PE PROVE Study. Catheterization and Cardiovascular Interventions, 2019, 93, 398-403.	1.7	3
24	Weekend effect in acute coronary syndrome: A meta-analysis of observational studies. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 432-442.	1.0	19
25	Vascular Access Site and Outcomes in 58,870 Patients Undergoing Percutaneous Coronary Intervention With a Previous History of Coronary Bypass Surgery. JACC: Cardiovascular Interventions, 2018, 11, 482-492.	2.9	22
26	Thyroid Hormones and Cardiovascular Function and Diseases. Journal of the American College of Cardiology, 2018, 71, 1781-1796.	2.8	272
27	Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database. Catheterization and Cardiovascular Interventions, 2018, 92, 659-665.	1.7	4
28	FDXR is a biomarker of radiation exposure in vivo. Scientific Reports, 2018, 8, 684.	3.3	89
29	152...Circulating non-classical monocytes are preferentially depleted from the circulation immediately after reperfusion in stemi patients and are associated with patient outcomes. , 2018, , .		0
30	Outcomes Following Percutaneous Coronary Intervention in Non-ST-Segment Elevation Myocardial Infarction Patients With Coronary Artery Bypass Grafts. Circulation: Cardiovascular Interventions, 2018, 11, e006824.	3.9	19
31	The impact of diabetes on the prognostic value of left ventricular function following percutaneous coronary intervention: Insights from the British Cardiovascular Intervention Society. Catheterization and Cardiovascular Interventions, 2018, 92, E393-E402.	1.7	1
32	Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis. Drug Safety, 2017, 40, 229-240.	3.2	24
33	The Relationship of Body Mass Index to Percutaneous Coronary Intervention Outcomes. JACC: Cardiovascular Interventions, 2017, 10, 1283-1292.	2.9	78
34	Thyroid hormones and cardiovascular disease. Nature Reviews Cardiology, 2017, 14, 39-55.	13.7	448
35	Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians. Heart, 2016, 102, 1648-1654.	2.9	21
36	Determinants and Outcomes of Stroke Following Percutaneous Coronary Intervention by Indication. Stroke, 2016, 47, 1500-1507.	2.0	28

#	ARTICLE	IF	CITATIONS
37	Changes in Arterial Access Site and Association With Mortality in the United Kingdom. <i>Circulation</i> , 2016, 133, 1655-1667.	1.6	71
38	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 232-244.	3.0	13
39	Impact of age on access site-related outcomes in 469,983 percutaneous coronary intervention procedures: Insights from the British Cardiovascular Intervention Society. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 965-972.	1.7	30
40	Stroke following percutaneous coronary intervention: type-specific incidence, outcomes and determinants seen by the British Cardiovascular Intervention Society 2007-12. <i>European Heart Journal</i> , 2015, 36, 1618-1628.	2.2	69
41	High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. <i>PLoS ONE</i> , 2015, 10, e0135037.	2.5	12